If you have been reading about prothymosin alpha and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
=== Solar kiln === A solar kiln is a cross between kiln drying and air drying. These kilns are a greenhouse with high-temperature fans and either vents or a condensing system. Solar kilns are slower and variable due to the weather, but are low cost. They use no grid electricity.
Substitution in position 4 of the benzyl affects analgesic potency in the following order: ethoxy > isopropyloxy > n-propyloxy > methoxy > methylthio > H/Cl/F > hydroxy. The most potent of the known compounds contain a nitro group in position 5. The replacement of benzimidazole with an indole has been known from studies conducted by Ciba AG since 1963.
It is common for photographs, notes, cards, and favourite personal items to be placed in the coffin with the deceased. Bulky and expensive items, such as electric guitars, are occasionally interred with a body. In some ways this mirrors the ancient practice of placing grave goods with a person for their use or enjoyment in the afterlife. In traditional Chinese culture, paper substitutes of the goods are buried or cremated with the deceased instead, as well as paper money specifically purchased for the occasion.
Sources: en.wikipedia.org
=== Bible verses === In-N-Out prints Bible citations in small print on areas of packaging (such as "John 3:16", "Proverbs 3:5", "Proverbs 24:16", "Nahum 1:7", "Luke 6:35" and "Revelation 3:20"). They are primarily found on the bottom underside of drink cups and the wrappers that hold their burgers together. This practice began in the 1980s during Rich Snyder's presidency, a reflection of the evangelical Christian beliefs held by the Snyder family.
==== United Kingdom ==== A large number of substances in the 25-NB class are Class A drugs in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971 or are otherwise covered by the Psychoactive Substances Act 2016.
=== P53 and p73 === p53 and p73 are tumor suppressor proteins and their degradation is tightly regulated by ubiquitination. Recently it was shown that their degradation can also occur via an ubiquitin-independent process; NQO1 blocks p53 and p73 degradation in the presence of NADH and protects them from 20S proteasomal degradation. This protein-protein interaction between p53 and NQO1 was non-catalytic.
Sources: en.wikipedia.org
== History == An early prominent example of an international organization is the Congress of Vienna of 1814–1815, which was an international diplomatic conference to reconstitute the European political order after the downfall of the French Emperor Napoleon. States then became the main decision makers who preferred to maintain their sovereignty as of 1648 at the Westphalian treaty that closed the Thirty Years' War in Europe. The Central Commission for Navigation on the Rhine, founded in 1815, is the world's oldest international organization still in operation. The oldest international organization established employing a treaty and creating a permanent secretariat with a global membership was the International Telecommunication Union, founded in 1865. The Universal Postal Union, established in 1874 as the General Postal Union, is the third oldest extant international organization. The first general international organization—addressing a variety of issues—was the League of Nations, founded on 10 January 1920 with a principal mission of maintaining world peace after the First World War. The United Nations followed this model after Second World War. This was signed on 26 June 1945, in San Francisco, at the conclusion of the United Nations Conference on International Organization, and came into force on 24 October 1945. Currently, the United Nations is the main IGO with its arms such as the Security Council (UNSC), General Assembly (UNGA), International Court of Justice (ICJ), Secretariat (UNSA), Trusteeship Council (UNTC), and Economic and Social Council (ECOSOC).
Halliwell was awarded the Public Administration Medal (Silver) in 2010 by the President of Singapore for contributions to Singapore and awarded the President's Science and Technology Medal (2013) by the President of Singapore "for distinguished sustained and exceptional contributions to Singapore's Science and Engineering landscape". Halliwell was conferred the Outstanding Service Award at the NUS University Awards on 8 September 2023. In 2008, Halliwell was awarded the "Lifetime Achievement Award" by the Society for Free Radical Biology and Medicine in the US for overall sustained excellence in the field. He was described as a "Research Pioneer" by the journal Antioxidants & Redox Signaling in 2011. Same year, he was also awarded the Ken Bowman Research Award for outstanding achievements in the field of cardiovascular research from the Institute of Cardiovascular Sciences (Canada) and NUS University Award – Outstanding Researcher Award. He was elected a fellow of the American Association for the Advancement of Science in 2012. Halliwell was awarded a Doctor of Science honoris causa by King's College London in 2018. He was again identified as a "Highly Cited Scientist" for cross-disciplinary work by Clarivate Analytics in 2018. He was honoured as a Citation Laureate (2021) for "pioneering research in free-radical chemistry including the role of free radicals and antioxidants in human disease".
Pynegabine (developmental code name HN37) is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of epilepsy in China. The drug is an analogue of flupirtine and retigabine (ezogabine). However, it shows 55-fold greater potency in activating Kv7.2 channels and 127-fold greater potency in activating Kv7.3 channels compared to retigabine in vitro. In addition, it shows improved chemical or metabolic stability compared to retigabine and in relation to this may have reduced toxicity in comparison. The drug is under development by the Shanghai Institute of Materia Medica and Hainan Haiyao. As of 2026, it is in phase 2 clinical trials for epilepsy.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.